With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Achromatopsia and advance AGTC’s preclinical
- Poster presentation highlights safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) - GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting
Ms. D’Oyley-Gay brings significant legal experience as well as business development and commercial operations expertise from both biotech and pharmaceutical companies GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC),
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
-Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022- -Company to host management update and webcast today at 8:00 a.m. ET - GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases,
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Oct. 14, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
Dr. Rachel Huckfeldt and Dr. Paul Yang to Present 12-Month Findings and Analysis from AGTC’s Clinical Trials GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials
